As clinical studies have indicated that crizotinib or ceritinib therapy could reduce chest, arm, and shoulder pain in non–small cell lung cancer patients (51–53), it will be important to confirm that ALK inhibition is analgesic in human patients. This evidence concerns the gene ALK and lung cancer.